XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.1

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

6 Months Ended

Mar. 31, 2025

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of revenues disaggregated by business operations and timing of revenue recognition

​

​	​	​	​	​	​	​
​	​	Three Month Period Ended:
​	​	March 31,		​	March 31,
​		2025			2024
Research and development services (over-time)	​	$	133,547	​	$	65,200
Clinical laboratory testing services (point-in-time)	​	​	—	​	​	6,440
Clinical laboratory testing services (over-time)	​	​	220,552	​	​	324,580
Product and authentication services (point-in-time):	​		​	​		​
Supply chain	​		290,229	​		275,259
Large Scale DNA Production	​	​	333,662	​	​	258,152
Asset Marking	​		5,384	​		—
Total	​	$	983,374	​	$	929,631

​

​	​	​	​	​	​	​
​	​	Six Month Period Ended:
​	​	March 31,		​	March 31,
​		2025			2024
Research and development services (over-time)	​	$	280,989	​	$	142,735
Clinical laboratory testing services (point-in-time)	​	​	1,746	​	​	18,560
Clinical laboratory testing services (over-time)	​	​	545,132	​	​	649,160
Product and authentication services (point-in-time):	​	​	​	​	​	​
Supply chain	​		1,013,078	​		742,746
Large Scale DNA Production	​		333,662	​		258,152
Asset marking	​	​	5,384	​	​	9,442
Total	​	$	2,179,991	​	$	1,820,795

Schedule of opening and closing contract balances

​

​	​	​	​	​	​	​	​	​	​	​	​
​	​	​	​	October 1,		​	March 31,		​	$
​		Balance sheet classification		2024			2025			change
Contract liabilities		Deferred revenue	​	$	252,785	​	$	206,285	​	$	46,500

Schedule of reconciliation of cash, cash equivalents and restricted cash to amounts shown in statement of cash flows

​

​	​	​	​	​	​	​
​		March 31,			September 30,
​	​	2025		​	2024
Cash and cash equivalents	​	$	6,823,260	​	$	6,431,095
Restricted cash	​		750,000	​		750,000
Total cash, cash equivalents and restricted cash	​	$	7,573,260	​	$	7,181,095

Schedule of anti-dilutive securities not included computation of net loss per share

​

​	​	​	​	​
​		2025		2024
Warrants	​	12,780,471	​	16,501
Stock options	​	2,124	​	2,187
Total	​	12,782,595	​	18,688

X

- Definition

Tabular disclosure of the components of cash, cash equivalents and restricted cash and cash equivalents.

+ References

No definition available.

+ Details

Name:	apdn_ScheduleOfCashCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock
Namespace Prefix:	apdn_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration